Welcome to our dedicated page for Virnetx Holding SEC filings (Ticker: VHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent litigation updates, royalties from licensing, and capitalized legal expenses make VirnetX Holding Corporation’s regulatory disclosures a dense read. Investors hunting for the true cost of enforcing its secure-communications patents—or for clues about fresh licensing deals—often scroll through hundreds of pages. Our platform surfaces the answers instantly, turning “VirnetX Holding SEC filings explained simply” from wishful thinking into reality.
Stock Titan’s AI reviews every document the moment it posts to EDGAR. Whether you need a “VirnetX Holding quarterly earnings report 10-Q filing” breakdown, a “VirnetX Holding 8-K material events explained” alert after a courtroom verdict, or “VirnetX Holding Form 4 insider transactions real-time” delivered as they happen, the engine highlights the sections that move the stock. Side-by-side financial tables, plain-language summaries, and keyword search help you understand VirnetX’s revenue concentration, litigation reserves, and deferred tax assets without drowning in jargon.
Use the annual report 10-K to see how Zero Trust products like War Room and Gabriel affect segment revenue, interrogate the proxy statement for “VirnetX Holding proxy statement executive compensation” details, or track “VirnetX Holding insider trading Form 4 transactions” ahead of settlement announcements. From “understanding VirnetX Holding SEC documents with AI” to performing a concise “VirnetX Holding earnings report filing analysis,” professionals rely on our platform to spot trends, gauge litigation risk, and act before the market reacts. “VirnetX Holding executive stock transactions Form 4” alerts, “VirnetX Holding annual report 10-K simplified” notes, and more are updated in real time—so you never miss a disclosure that matters.
VirnetX Holding Corporation reported results for the quarter ended June 30, 2025, showing continued operating losses while maintaining a multi-month cash runway. Revenue was immaterial at $48 thousand for the six months ended June 30, 2025. Operating expenses totaled $8.0 million for the six months, driven by $2.47 million in R&D and $5.57 million in selling, general and administrative expenses.
The company recorded a six-month net loss of $7.3 million (basic loss per share $1.99), and used $6.8 million of cash in operating activities during the period. At June 30, 2025, VirnetX held $17.3 million in cash and $13.9 million of investments available for sale, totaling $31.2 million in liquid resources. Total assets were $41.8 million, total liabilities $8.6 million, and stockholders' equity $33.2 million. The company reported an accumulated deficit of $212.0 million and maintains a full valuation allowance on its deferred tax assets. Management describes ongoing commercialization efforts for VirnetX One™, War Room™, and VirnetX Matrix™, a CRADA with AFRL through 2030, and investments in AI/ML partnerships to support DoD-focused product adoption.
VirnetX Holding Corp Chief Scientist Robert D. Short III reported a Form 4 filing on June 28, 2025, disclosing transactions from June 23, 2025. The insider disposed of 8 shares of Common Stock at $8.06 per share through a withholding transaction (Code F).
Key details of the transaction:
- The shares were withheld by the company for tax purposes related to previously awarded restricted stock units
- Following the transaction, Short holds 31,898 shares directly
- Additionally owns 11,278 shares indirectly through The Short Revocable Living Trust
The transaction was executed under standard tax withholding procedures and does not represent an open market sale by the insider. The filing was signed by Kendall Larsen as attorney-in-fact for Robert D. Short III on June 25, 2025.